250
Participants
Start Date
March 31, 2006
Primary Completion Date
June 30, 2008
Study Completion Date
June 30, 2008
lecozotan SR (SRA-333)
one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
Gascon
Pilar
Larrea
Randwick
Hornsby
Calle Adolfo Alsina
Johannesburg
East Gosford
Av. Belgrano
Victoria
Cervino
Nueva York
Puerto Galván
Adelaide
Somerset West
Cape Town
Bloemfontein
Staten Island
Cedarhurst
Albany
Philadelphia
Winston-Salem
Madrid
Madrid
Toulouse
Orlando
Hallandale
Hialeah
Bordeaux
South Miami
Miami Beach
Miami
Jacksonville
Fort Lauderdale
West Palm Beach
Delray Beach
Tampa
Fort Myers
Sarasota
Montpellier
Memphis
Columbus
St Louis
Kuopio
Tulsa
Houston
Joensuu
Phoenix
Tucson
La Jolla
Costa Mesa
Orange
Fresno
Long Branch
Manchester Twp.
East Providence
Bennington
Buenos Aires
Edmonton
Medicine Hat
Moncton
Ottawa
Montreal
Helsinki
Nice
Roma
Roma
Gdansk - Wrzeszcz
Krakow
Krakow
Lodz
Lublin
Sopot
Szczecin
Barcelona
Barcelona
Barcelona
Barcelona
Belfast
Glasgow
Sheffield
Southampton
Swindon
Lead Sponsor
Pfizer
INDUSTRY